Morse Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.81M Buy
17,535
+2,210
+14% +$490K 0.79% 37
2025
Q4
$3.5M Buy
15,325
+2,057
+16% +$469K 0.7% 44
2025
Q3
$3.07M Buy
13,268
+6,270
+90% +$1.28M 0.61% 47
2025
Q2
$1.3M Sell
6,998
-150
-2% -$27.9K 0.28% 78
2025
Q1
$1.5M Sell
7,148
-165
-2% -$32.1K 0.38% 63
2024
Q4
$1.3M Sell
7,313
-250
-3% -$46K 0.3% 74
2024
Q3
$1.49M Buy
7,563
+175
+2% +$32.7K 0.32% 72
2024
Q2
$1.27M Sell
7,388
-500
-6% -$82.8K 0.31% 72
2024
Q1
$1.44M Sell
7,888
-2
-0% -$345 0.37% 66
2023
Q4
$1.22M Sell
7,890
-1,010
-11% -$147K 0.36% 67
2023
Q3
$1.33M Sell
8,900
-13,806
-61% -$2.03M 0.42% 64
2023
Q2
$3.06M Sell
22,706
-34,353
-60% -$5.04M 0.93% 38
2023
Q1
$9.09M Sell
57,059
-1,280
-2% -$196K 3.07% 4
2022
Q4
$9.43M Sell
58,339
-437
-0.7% -$67K 3.42% 3
2022
Q3
$7.89M Sell
58,776
-240
-0.4% -$34.4K 2.98% 6
2022
Q2
$9.04M Buy
59,016
+2,190
+4% +$335K 2.9% 7
2022
Q1
$9.21M Sell
56,826
-2,625
-4% -$381K 2.29% 7
2021
Q4
$8.05M Buy
59,451
+625
+1% +$73.8K 1.8% 14
2021
Q3
$6.35M Sell
58,826
-2,473
-4% -$283K 1.51% 16
2021
Q2
$6.91M Sell
61,299
-1,270
-2% -$143K 1.67% 14
2021
Q1
$6.77M Buy
62,569
+5,085
+9% +$544K 1.74% 15
2020
Q4
$6.16M Buy
57,484
+6,645
+13% +$639K 1.71% 15
2020
Q3
$4.45M Sell
50,839
-420
-0.8% -$39.5K 1.43% 18
2020
Q2
$5.03M Buy
51,259
+8,454
+20% +$744K 1.79% 17
2020
Q1
$3.26M Buy
42,805
+4,000
+10% +$341K 1.56% 18
2019
Q4
$3.44M Buy
38,805
+27,055
+230% +$2.25M 1.18% 25
2019
Q3
$890K Hold
11,750
0.33% 70
2019
Q2
$854K Sell
11,750
-200
-2% -$15.7K 0.25% 83
2019
Q1
$963K Sell
11,950
-15,535
-57% -$1.27M 0.29% 73
2018
Q4
$2.53M Sell
27,485
-2,680
-9% -$236K 0.9% 35
2018
Q3
$2.85M Sell
30,165
-19,795
-40% -$1.88M 0.75% 43
2018
Q2
$4.63M Sell
49,960
-13,200
-21% -$1.29M 1.27% 24
2018
Q1
$5.98M Buy
63,160
+615
+1% +$67.6K 1.66% 15
2017
Q4
$6.05M Buy
62,545
+1,035
+2% +$97.5K 1.68% 17
2017
Q3
$5.47M Buy
61,510
+8,120
+15% +$618K 1.63% 16
2017
Q2
$3.87M Buy
53,390
+14,785
+38% +$994K 1.26% 26
2017
Q1
$2.52M Buy
+38,605
New +$2.43M 0.86% 40

Other funds holding ABBV

Morse Asset Management's ABBV Position: Q1 2026 in Review

Morse Asset Management increased its AbbVie (ABBV) stake by 14% in Q1 2026, buying an estimated $490K and bringing the position to 17,535 shares worth $3.81M. The position accounts for 0.79% of the portfolio, ranked #37.

Morse Asset Management first reported a position in ABBV in Q1 2017 and has held it in 37 quarters since. The position peaked at $9.43M in Q4 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Morse Asset Management held 17,535 shares of AbbVie worth $3.81M as of Q1 2026.
  • Morse Asset Management bought 2,210 AbbVie shares in Q1 2026, an estimated $490K.
  • AbbVie made up 0.79% of Morse Asset Management's portfolio in Q1 2026, its #37 holding.
  • Morse Asset Management first reported a position in AbbVie in Q1 2017 and has held it in 37 quarters since.
  • Morse Asset Management's AbbVie position peaked at $9.43M in Q4 2022.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Morse Asset Management's 13F filing for Q1 2026, filed 14 May 2026.